Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FTT001
MIFTS: 61

Fatty Liver Disease

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fatty Liver Disease

About this section

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 42 15
Fatty Liver 74 43 71
Fatty Liver, Alcoholic 43 71
Alcoholic Fatty Liver 12 32
Fatty Change of Liver 12
Fatty Liver Alcoholic 54
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 71

Classifications:

MalaCards categories:
Global: Metabolic diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9452
ICD9CM 34 571.0
SNOMED-CT 67 50325005
ICD10 32 K70.0 K76.0
UMLS 71 C0015695 C0015696 C2711227
Sources

Summaries for Fatty Liver Disease

About this section
MedlinePlus : 42 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? The cause of nonalcoholic fatty liver disease (NAFLD) is unknown. Researchers do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to fatty liver disease, nonalcoholic 1 and non-alcoholic fatty liver disease. An important gene associated with Fatty Liver Disease is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Parkinson disease. The drugs Milk thistle and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 74 Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Sources

Related Diseases for Fatty Liver Disease

About this section

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 35.5 PPARA PNPLA3 LEP INS ADIPOQ
2 non-alcoholic fatty liver disease 34.5 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H3
3 non-alcoholic steatohepatitis 34.2 TNF PPARA PNPLA3 MAPK8 LEPR IRS1
4 hyperlipidemia, familial combined, 3 33.3 PPARA LEPR INS ADIPOQ
5 liver disease 33.2 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H3
6 lipid metabolism disorder 32.5 SREBF1 PPARA LEP IRS1 INS IL6
7 viral hepatitis 32.2 TNF PNPLA3 INS IL6 IL1B
8 atherosclerosis susceptibility 32.1 TNF PPARA LEP INS IL6 IL1B
9 polycystic ovary syndrome 32.0 LEP IRS2 IRS1 INS ADIPOQ
10 chronic kidney disease 32.0 TNF LEPR LEP INS IL6 IL1B
11 liver cirrhosis 32.0 MALAT1 LEPR LEP CYP2E1 ADIPOQ
12 hyperinsulinism 31.9 SREBF1 PPARA LEPR LEP IRS2 IRS1
13 sleep apnea 31.9 TNF LEPR LEP INS IL6 IL1B
14 glucose intolerance 31.9 TNF LEPR LEP IRS1 INS IL6
15 arteries, anomalies of 31.8 TNF LEP INS IL6 IL1B ADIPOQ
16 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.7 LEP INS ADIPOQ
17 vascular disease 31.7 TNF LEP INS IL6 ADIPOQ
18 lipoprotein quantitative trait locus 31.7 TNF IRS1 IL6 IL1B
19 proteasome-associated autoinflammatory syndrome 1 31.6 TNF PPARA IL6 IL1B ADIPOQ
20 leptin deficiency or dysfunction 31.5 TNF SREBF1 PPARA LEPR LEP IRS2
21 alcoholic hepatitis 31.5 TNF PNPLA3 IL6 IL1B CYP2E1
22 acanthosis nigricans 31.5 LEP INS ADIPOQ
23 choline deficiency disease 31.5 SREBF1 PPARA INS
24 inflammatory bowel disease 31.5 XBP1 TNF PPARA MAPK8 LEP IL6
25 end stage renal disease 31.5 TNF INS IL6 ADIPOQ
26 gout 31.5 TNF INS IL6 IL1B
27 gastroesophageal reflux 31.4 TNF IL6 IL1B ADIPOQ
28 hyperglycemia 31.4 MALAT1 LEP IRS2 IRS1 INS IL6
29 arteriosclerosis 31.4 PPARA INS IL6 ADIPOQ
30 heart disease 31.3 TNF PPARA LEP INS IL6 IL1B
31 apnea, obstructive sleep 31.3 TNF LEP INS IL6 IL1B ADIPOQ
32 hepatitis a 31.3 TNF INS IL1B
33 hypothalamic obesity 31.3 LEPR LEP INS
34 sleep disorder 31.3 TNF LEP INS IL6 IL1B ADIPOQ
35 gestational diabetes 31.3 TNF LEPR LEP IRS2 IRS1 INS
36 insulin-like growth factor i 31.3 LEP IRS2 IRS1 INS
37 congestive heart failure 31.2 TNF INS IL6 IL1B
38 celiac disease 1 31.2 TNF INS IL6 IL1B
39 abdominal obesity-metabolic syndrome 1 31.2 PPARA LEPR LEP INS ADIPOQ
40 retinal vascular disease 31.2 TNF INS IL6 IL1B
41 cerebrovascular disease 31.2 TNF LEP INS IL6 ADIPOQ
42 acute pancreatitis 31.1 TNF INS IL6 IL1B
43 body mass index quantitative trait locus 11 31.1 TNF SREBF1 PPARA PNPLA3 MLXIPL MAPK8
44 overnutrition 31.1 TNF SREBF1 PPARA MAPK8 LEPR LEP
45 severe pre-eclampsia 31.1 LEPR LEP ADIPOQ
46 hyperthyroidism 31.1 TNF LEP INS IL6
47 pulmonary disease, chronic obstructive 31.1 TNF INS IL6 IL1B CYP2E1
48 familial hyperlipidemia 31.1 SREBF1 PPARA LEP INS ADIPOQ
49 endometritis 31.1 TNF IL6 IL1B
50 genetic obesity 31.0 LEPR LEP

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcoholic Hepatitis Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease
Sources

Symptoms & Phenotypes for Fatty Liver Disease

About this section

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-124 9.66 XBP1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 9.66 IRS2 NR1H3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.66 NR1H3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.66 XBP1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.66 IRS2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-183 9.66 NR1H3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 9.66 XBP1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 9.66 NR1H3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-199 9.66 XBP1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.66 NR1H3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.66 NR1H3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.66 IRS2 NR1H3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.66 NR1H3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.66 NR1H3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.66 IRS2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 9.66 NR1H3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.66 IRS2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 9.66 NR1H3
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.66 IRS2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.66 IRS2

MGI Mouse Phenotypes related to Fatty Liver Disease:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
2 adipose tissue MP:0005375 10.46 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
3 growth/size/body region MP:0005378 10.43 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
4 behavior/neurological MP:0005386 10.42 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
5 cardiovascular system MP:0005385 10.41 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
6 cellular MP:0005384 10.4 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
7 liver/biliary system MP:0005370 10.39 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
8 endocrine/exocrine gland MP:0005379 10.31 ADIPOQ ADIPOR2 IL6 INS IRS1 IRS2
9 mortality/aging MP:0010768 10.31 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
10 hematopoietic system MP:0005397 10.29 ADIPOQ ADIPOR1 IL1B IL6 INS IRS1
11 immune system MP:0005387 10.29 ADIPOQ IL1B IL6 INS IRS1 IRS2
12 integument MP:0010771 10.2 ADIPOQ IL1B IL6 INS IRS2 LEP
13 muscle MP:0005369 10.18 ADIPOQ ADIPOR1 IL6 INS IRS1 IRS2
14 digestive/alimentary MP:0005381 10.15 IL6 INS LEP LEPR MAPK8 MLXIPL
15 nervous system MP:0003631 10.03 ADIPOQ ADIPOR2 IL1B IL6 INS IRS2
16 neoplasm MP:0002006 9.97 ADIPOQ CYP2E1 IL1B IL6 LEP LEPR
17 renal/urinary system MP:0005367 9.81 ADIPOQ IL6 INS IRS2 LEP LEPR
18 skeleton MP:0005390 9.73 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
19 vision/eye MP:0005391 9.32 ADIPOR1 IL6 INS IRS1 IRS2 LEP
Sources

Drugs & Therapeutics for Fatty Liver Disease

About this section

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 420)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Losartan Approved Phase 4 114798-26-4 3961
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Glucagon Approved Phase 4 16941-32-5
7
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
10
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Insulin aspart Approved Phase 4 116094-23-6 16132418
14
Insulin detemir Approved Phase 4 169148-63-4 5311023
15
Gliclazide Approved Phase 4 21187-98-4 3475
16
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
20
Ribavirin Approved Phase 4 36791-04-5 37542
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
22
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
23
Tamoxifen Approved Phase 4 10540-29-1 2733526
24
Ergotamine Approved Phase 4 113-15-5 8223
25
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
26
Nortriptyline Approved Phase 4 72-69-5 4543
27
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
28
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
31
Lenvatinib Approved, Investigational Phase 4 417716-92-8
32
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
33
Empagliflozin Approved Phase 4 864070-44-0
34
Alogliptin Approved Phase 4 850649-61-5 11450633
35
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
36
Methyltestosterone Approved Phase 4 58-18-4 6010
37
Testosterone enanthate Approved Phase 4 315-37-7 9416
38
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
39
Dulaglutide Approved, Investigational Phase 4 923950-08-7
40
Metformin Approved Phase 4 657-24-9 14219 4091
41
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
42
Insulin glargine Approved Phase 4 160337-95-1
43
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
44
Zinc Approved, Investigational Phase 4 7440-66-6 32051
45
Saxagliptin Approved Phase 4 361442-04-8 11243969
46
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
47
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
48
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
49
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 1246)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
7 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
8 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
9 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
10 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
11 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
14 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
15 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
16 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
17 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
18 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
19 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
20 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
21 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
22 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
23 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
24 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
25 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
26 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
27 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
28 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
29 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
30 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
31 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
32 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
33 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
34 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
35 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
36 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
37 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
38 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
39 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
40 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
41 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
42 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
43 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
44 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
45 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
46 Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
47 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
48 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
49 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
50 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Sources

Genetic Tests for Fatty Liver Disease

About this section
Sources

Anatomical Context for Fatty Liver Disease

About this section

MalaCards organs/tissues related to Fatty Liver Disease:

40
Liver, Testes, Kidney, Heart, Endothelial, Ovary, Bone
Sources

Publications for Fatty Liver Disease

About this section

Articles related to Fatty Liver Disease:

(show top 50) (show all 27386)
# Title Authors PMID Year
1
Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis. 61 42
32384501 2020
2
Association of resting heart rate with nonalcoholic fatty liver disease in postmenopausal women. 61 42
32243369 2020
3
Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. 42 61
32245585 2020
4
Adiponectin: a key adipokine in alcoholic fatty liver. 54 61
19491377 2009
5
The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. 61 54
19561788 2009
6
Molecular mechanisms of alcoholic fatty liver. 61 54
19032584 2009
7
Adiponectin and alcoholic fatty liver disease. 54 61
18709650 2008
8
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? 54 61
16116627 2005
9
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. 61 54
16108051 2005
10
Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. 54 61
15670659 2004
11
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 54 61
15040041 2004
12
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. 54 61
14606109 2003
13
Nuclear magnetic resonance (NMR)-based metabolome profile evaluation in dairy cows with and without displaced abomasum. 61
31858882 2020
14
Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. 61
32489856 2020
15
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
16
Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. 61
32000567 2020
17
Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. 61
32387461 2020
18
GSK-3 in liver diseases: Friend or foe? 61
32417256 2020
19
Effect of PFOA on DNA Methylation and Alternative Splicing in Mouse Liver. 61
32320774 2020
20
PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice. 61
32445755 2020
21
Exposure to 2,3,3',4,4',5-hexachlorobiphenyl promotes nonalcoholic fatty liver disease development in C57BL/6 mice. 61
32304952 2020
22
Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. 61
32145387 2020
23
Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. 61
32460191 2020
24
Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway. 61
32521450 2020
25
Long-term bisphenol S exposure aggravates non-alcoholic fatty liver by regulating lipid metabolism and inducing endoplasmic reticulum stress response with activation of unfolded protein response in male zebrafish. 61
32283406 2020
26
GanMeijian ameliorates lipid accumulation and oxidative damage in alcoholic fatty liver disease in Wistar rats. 61
32360617 2020
27
The influence of probiotics on bile acids in diseases and aging. 61
32504921 2020
28
Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. 61
32437790 2020
29
Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis. 61
32434697 2020
30
TLR4 knockout upregulates the expression of Mfn2 and PGC-1α in a high-fat diet and ischemia-reperfusion mice model of liver injury. 61
32437795 2020
31
Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. 61
32438122 2020
32
CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease. 61
32417373 2020
33
The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis. 61
32306299 2020
34
Partial leptin deficiency confers resistance to diet-induced obesity in mice. 61
32289482 2020
35
Bariatric Surgery Decreases the Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis. 61
32559048 2020
36
The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related? 61
32026275 2020
37
[New pharmacological treatment options for nonalcoholic fatty liver disease]. 61
32409850 2020
38
Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. 61
32376267 2020
39
Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. 61
32229037 2020
40
Caveats for the implementation of global strategies against non-alcoholic fatty liver disease. 61
32229039 2020
41
Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". 61
32280051 2020
42
Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. 61
32124081 2020
43
ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK/mTOR mediated autophagy. 61
32304762 2020
44
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. 61
32339855 2020
45
The offspring from rats fed a fatty diet display impairments in the activation of liver peroxisome proliferator activated receptor alpha and features of fatty liver disease. 61
32298755 2020
46
Uncovering the PIDDosome and caspase-2 as regulators of organogenesis and cellular differentiation. 61
32415279 2020
47
Sirtuin 3 improves fatty acid metabolism in response to high nonesterified fatty acids in calf hepatocytes by modulating gene expression. 61
32331890 2020
48
Improving high-fat diet-induced obesity and fatty liver by adipose tissue targeted delivery of vascular endothelial growth factor-B. 61
32305525 2020
49
Disruption of hepatic one-carbon metabolism impairs mitochondrial function and enhances macrophage activity in methionine-choline-deficient mice. 61
32422424 2020
50
Pyrvinium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/β-catenin signaling crosstalk. 61
32240652 2020
Sources

Variations for Fatty Liver Disease

About this section
Sources

Expression for Fatty Liver Disease

About this section
Search GEO for disease gene expression data for Fatty Liver Disease.
Sources

Pathways for Fatty Liver Disease

About this section

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 65
Show member pathways
 13.52 TNF SREBF1 PPARA LEP IRS2 IRS1
2
Parkinson disease 36
Show member pathways
 13.13 XBP1 TNF MAPK8 IRS2 IRS1 INS
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.08 TNF PPARA NR1H3 MAPK8 IL6 IL1B
4
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.73 TNF LEP IRS2 IRS1 INS IL6
5
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 12.64 XBP1 TNF SREBF1 PPARA NR1H3 MLXIPL
6
Immune response IL-23 signaling pathway 22
Show member pathways
 12.6 TNF MAPK8 IRS2 IL6 IL1B
7
Glucose / Energy Metabolism 4
12.54 SREBF1 IRS2 IRS1 INS ADIPOQ
8
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.49 XBP1 SREBF1 NR1H3 MLXIPL MAPK8 IRS2
9
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.48 SREBF1 LEPR LEP IRS2 IRS1 INS
10
Prolactin Signaling Pathway 36 1
Show member pathways
 12.47 MAPK8 LEPR LEP IRS2 IRS1 INS
11
IL-17 Family Signaling Pathways 64
Show member pathways
 12.36 TNF MAPK8 IL6 IL1B
12
Folate Metabolism 1
Show member pathways
 12.35 TNF INS IL6 IL1B
13
Integration of energy metabolism 65
Show member pathways
 12.35 MLXIPL INS ADIPOR2 ADIPOR1 ADIPOQ
14
Salmonella infection (KEGG) 36
12.33 TNF MAPK8 IL6 IL1B
16
Pathogenic Escherichia coli infection 36
12.29 TNF MAPK8 IL6 IL1B
17
NOD-like receptor signaling pathway 36
12.25 TNF MAPK8 IL6 IL1B
18
Tuberculosis 36
12.25 TNF MAPK8 IL6 IL1B
19
C-type lectin receptor signaling pathway 36
Show member pathways
 12.23 TNF MAPK8 IL6 IL1B
20
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.23 TNF SREBF1 MAPK8 IRS1
21
AMPK Enzyme Complex Pathway 63
Show member pathways
 12.22 LEP IRS2 IRS1 INS
22
Longevity regulating pathway 36
Show member pathways
 12.15 IRS2 IRS1 INS ADIPOR2 ADIPOR1 ADIPOQ
23
Autophagy - animal 36
12.1 MAPK8 IRS2 IRS1 INS
24
FoxO signaling pathway 36
Show member pathways
 12.06 MAPK8 IRS2 IRS1 INS IL6
25
Yersinia infection 36
12.01 TNF MAPK8 IL6 IL1B
26
Spinal Cord Injury 1
12.01 TNF LEP IL6 IL1B
27
Insulin resistance 36
Show member pathways
 12 TNF SREBF1 PPARA NR1H3 MLXIPL MAPK8
28
TNF signaling pathway 36
11.96 TNF MAPK8 IL6 IL1B
29
AGE-RAGE signaling pathway in diabetic complications 36
11.91 TNF MAPK8 IL6 IL1B
30
Type II diabetes mellitus 36 1
Show member pathways
 11.89 TNF MAPK8 IRS2 IRS1 INS ADIPOQ
31
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.88 LEP INS IL6 ADIPOQ
32
Adipogenesis 1
11.82 TNF SREBF1 PPARA PNPLA3 NR1H3 LEP
33
PPAR signaling pathway 36
11.79 PPARA NR1H3 ADIPOQ
34
Dendritic Cells Developmental Lineage Pathway 64
11.77 TNF IL6 IL1B
35
Pertussis 36
11.75 TNF MAPK8 IL6 IL1B
36
AGE/RAGE pathway 1
11.71 MAPK8 IRS1 INS
37
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 TNF IL6 IL1B
38
Adipocytokine signaling pathway 36
11.69 TNF PPARA MAPK8 LEPR LEP IRS2
39
Lung fibrosis 1
11.68 TNF IL6 IL1B
40
Legionellosis 36
11.63 TNF IL6 IL1B
41
Regulation of lipolysis in adipocytes 36
11.62 IRS2 IRS1 INS
42
ATF-2 transcription factor network 1
11.61 MAPK8 INS IL6
43
Photodynamic therapy-induced AP-1 survival signaling. 1
11.57 TNF MAPK8 IL6
44
Malaria 36
11.56 TNF IL6 IL1B
45
Development_Leptin signaling via PI3K-dependent pathway 22
11.56 LEPR LEP IRS2 IRS1
46
Interleukin-10 signaling 65
11.55 TNF IL6 IL1B
47
Signaling events mediated by PTP1B 1
11.54 LEPR LEP IRS1 INS
48
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 TNF IL6 IL1B
49
Signaling events regulated by Ret tyrosine kinase 1
11.42 MAPK8 IRS2 IRS1
50
African trypanosomiasis 36
11.4 TNF IL6 IL1B
Sources

GO Terms for Fatty Liver Disease

About this section

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 XBP1 TNF SREBF1 PPARA NR1H3 MLXIPL
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.22 TNF SREBF1 PPARA NR1H3 MLXIPL LEP
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF SREBF1 PPARA NR1H3 MLXIPL IL6
4 positive regulation of gene expression GO:0010628 10.13 TNF MAPK8 INS IL6 IL1B
5 MAPK cascade GO:0000165 10.06 TNF MAPK8 IRS2 IRS1 IL1B
6 positive regulation of cell migration GO:0030335 10.04 XBP1 IRS2 INS IL1B
7 positive regulation of cell proliferation GO:0008284 10.03 XBP1 MLXIPL LEP IRS2 IRS1 INS
8 fatty acid metabolic process GO:0006631 10.01 PPARA CYP2E1 ADIPOR2 ADIPOR1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF INS IL6 IL1B
10 positive regulation of protein phosphorylation GO:0001934 9.98 TNF LEPR LEP IL1B ADIPOQ
11 positive regulation of protein kinase B signaling GO:0051897 9.97 TNF LEP IRS2 IRS1 INS
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.94 TNF LEP IRS2 INS
13 insulin receptor signaling pathway GO:0008286 9.94 SREBF1 IRS2 IRS1 INS
14 response to nutrient GO:0007584 9.91 LEP ADIPOR2 ADIPOQ
15 response to insulin GO:0032868 9.91 PPARA LEP IRS1
16 lipid metabolic process GO:0006629 9.91 XBP1 SREBF1 PPARA PNPLA3 NR1H3 LEP
17 response to glucose GO:0009749 9.9 SREBF1 IRS2 ADIPOQ
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 TNF LEP IL6
19 response to nutrient levels GO:0031667 9.89 PPARA LEP ADIPOQ
20 response to glucocorticoid GO:0051384 9.89 TNF IL6 ADIPOQ
21 regulation of circadian rhythm GO:0042752 9.89 PPARA NR1H3 MAPK8
22 positive regulation of T cell proliferation GO:0042102 9.89 LEP IL6 IL1B
23 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
24 regulation of insulin secretion GO:0050796 9.88 TNF SREBF1 LEP IL1B
25 positive regulation of cold-induced thermogenesis GO:0120162 9.88 LEPR LEP ADIPOR2 ADIPOR1 ADIPOQ
26 cellular response to lipopolysaccharide GO:0071222 9.88 XBP1 TNF NR1H3 MAPK8 IL6 IL1B
27 negative regulation of fat cell differentiation GO:0045599 9.87 TNF IL6 ADIPOQ
28 hormone-mediated signaling pathway GO:0009755 9.87 PPARA ADIPOR2 ADIPOR1
29 lipid homeostasis GO:0055088 9.86 PNPLA3 NR1H3 IRS2
30 positive regulation of interleukin-6 secretion GO:2000778 9.85 XBP1 TNF IL1B
31 intracellular receptor signaling pathway GO:0030522 9.85 SREBF1 PPARA NR1H3
32 response to lipid GO:0033993 9.84 SREBF1 PPARA NR1H3
33 positive regulation of interleukin-8 production GO:0032757 9.83 TNF IL1B ADIPOQ
34 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 IL1B
35 positive regulation of glial cell proliferation GO:0060252 9.81 TNF IL6 IL1B
36 negative regulation of gluconeogenesis GO:0045721 9.8 LEPR INS ADIPOQ
37 fatty acid homeostasis GO:0055089 9.79 XBP1 MLXIPL INS
38 negative regulation of lipid catabolic process GO:0050995 9.79 TNF INS IL1B
39 positive regulation of glycogen biosynthetic process GO:0045725 9.78 IRS2 IRS1 INS
40 positive regulation of cellular protein metabolic process GO:0032270 9.77 NR1H3 INS ADIPOQ
41 fatty acid oxidation GO:0019395 9.77 ADIPOR2 ADIPOR1 ADIPOQ
42 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF LEP IL6 ADIPOR1
43 cellular response to leptin stimulus GO:0044320 9.74 LEPR LEP
44 sexual reproduction GO:0019953 9.74 LEPR LEP
45 negative regulation of appetite GO:0032099 9.73 PPARA LEP
46 positive regulation of glucose metabolic process GO:0010907 9.73 IRS2 IRS1
47 negative regulation of cholesterol storage GO:0010887 9.73 PPARA NR1H3
48 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 PPARA NR1H3 ADIPOQ
49 negative regulation of synaptic transmission GO:0050805 9.72 IL1B ADIPOQ
50 interleukin-6 production GO:0032635 9.72 LEP IL1B

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.71 PPARA NR1H3 ADIPOR2 ADIPOR1
2 cytokine activity GO:0005125 9.67 TNF IL6 IL1B ADIPOQ
3 nuclear receptor activity GO:0004879 9.5 SREBF1 PPARA NR1H3
4 adiponectin binding GO:0055100 9.26 ADIPOR2 ADIPOR1
5 adipokinetic hormone receptor activity GO:0097003 9.16 ADIPOR2 ADIPOR1
6 sterol response element binding GO:0032810 8.96 SREBF1 NR1H3
7 insulin receptor binding GO:0005158 8.8 IRS2 IRS1 INS
Sources

Sources for Fatty Liver Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....